<!--HTML document created with Certent Disclosure Management 6.5.8.2-->
<!--Created on: 2/10/2017 6:22:02 AM-->
<html>
	<head>
		<title>
			8K 2017-02-10
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;">
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 1pt">
						<a name="_GoBack"></a><font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;line-height:100%;text-align:center;font-weight:bold;text-indent:36pt;font-family:Times New Roman;font-size: 17pt">
						<font style="display: inline;">UNITED STATES</font><br /><font style="display: inline;"></font><font style="display: inline;">SECURITIES AND EXCHANGE COMMISSION</font></p>
					<p style="margin:12pt 0pt 0pt;text-align:center;font-weight:bold;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;">Washington, D.C. 20549</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;text-align:center;font-weight:bold;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;">_______________________</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:3pt 0pt 0pt;line-height:100%;text-align:center;font-weight:bold;text-indent:36pt;font-family:Times New Roman;font-size: 17pt">
						<font style="display: inline;">FORM 8-K</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;text-align:center;font-weight:bold;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;">_______________________</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:6pt 0pt 0pt;text-align:center;font-weight:bold;text-indent:36pt;font-family:Times New Roman;font-size: 13pt">
						<font style="display: inline;font-size:13pt;">CURRENT REPORT</font><font style="display: inline;font-size:12pt;">&nbsp;</font></p>
					<p style="margin:12pt 0pt 0pt;text-align:center;font-weight:bold;text-indent:36pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-size:12pt;">Pursuant to S</font><font style="display: inline;font-size:12pt;">ection 13 or 15(d) </font><br /><font style="display: inline;font-size:12pt;"></font><font style="display: inline;font-size:12pt;">of the</font><font style="display: inline;font-size:12pt;"> Securities Exchange A</font><font style="display: inline;font-size:12pt;">ct of 1934</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;text-align:center;font-weight:bold;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-weight:normal;font-size:11pt;">_______________________</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;text-align:center;font-weight:bold;text-indent:36pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-size:12pt;">Date of Report (date of earliest event reported): </font><font style="display: inline;font-size:12pt;">February 7</font><font style="display: inline;font-size:12pt;">, 2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;text-align:center;font-weight:bold;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;">_______________________</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:4.5pt 18pt 0pt 22.5pt;text-align:center;text-indent:36pt;font-family:Times New Roman;font-size: 24pt">
						<font style="display: inline;font-weight:bold;font-size:24pt;">Pulse Biosciences, Inc.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;text-align:center;font-weight:bold;text-indent:36pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:normal;">(Exact name of registrant as specified in its charter)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:22.95pt;padding:0pt;">
					<p style="margin:0pt;text-indent:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;">_______________________</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:27.76%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-indent:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:08.38%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-indent:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:28.08%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-indent:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.38%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-indent:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:27.40%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-indent:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:27.76%;padding:0pt;">
					<p style="margin:0pt;text-indent:0pt;text-align:center;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-size:9.5pt;">Nevada</font></p>
				</td>
				<td valign="bottom" style="width:08.38%;padding:0pt;">
					<p style="margin:0pt;text-indent:0pt;font-family:Times New Roman;font-size: 6pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:28.08%;padding:0pt;">
					<p style="margin:0pt;text-indent:0pt;text-align:center;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-size:9.5pt;">001-37744</font></p>
				</td>
				<td valign="bottom" style="width:08.38%;padding:0pt;">
					<p style="margin:0pt;text-indent:0pt;font-family:Times New Roman;font-size: 6pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:27.40%;padding:0pt;">
					<p style="margin:0pt;text-indent:0pt;text-align:center;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-size:9.5pt;">46-5696597</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:27.76%;padding:0pt;">
					<p style="margin:0pt;text-indent:0pt;text-align:center;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;font-weight:bold;font-size:7pt;">(State or other jurisdiction</font></p>
					<p style="margin:0pt;text-indent:0pt;text-align:center;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;font-weight:bold;font-size:7pt;">of incorporation)</font></p>
				</td>
				<td valign="bottom" style="width:08.38%;padding:0pt;">
					<p style="margin:0pt;text-indent:0pt;font-family:Times New Roman;font-size: 6pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:28.08%;padding:0pt;">
					<p style="margin:0pt;text-indent:0pt;text-align:center;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;font-weight:bold;font-size:7pt;">(Commission</font></p>
					<p style="margin:0pt;text-indent:0pt;text-align:center;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;font-weight:bold;font-size:7pt;">File Number)</font></p>
				</td>
				<td valign="bottom" style="width:08.38%;padding:0pt;">
					<p style="margin:0pt;text-indent:0pt;font-family:Times New Roman;font-size: 6pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:27.40%;padding:0pt;">
					<p style="margin:0pt;text-indent:0pt;text-align:center;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;font-weight:bold;font-size:7pt;">(IRS Employer</font></p>
					<p style="margin:0pt;text-indent:0pt;text-align:center;font-family:Times New Roman;font-size: 7pt">
						<font style="display: inline;font-weight:bold;font-size:7pt;">Identification No.)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 1.45pt 0pt 0pt;text-indent:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">849 Mitten Road</font>
		</p>
		<p style="margin:0pt 1.6pt 0pt 0pt;text-indent:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Burlingame, California 94010</font>
		</p>
		<p style="margin:0pt 1.6pt 0pt 0pt;text-indent:0pt;text-align:center;font-family:Times New Roman;font-size: 7pt">
			<font style="display: inline;font-weight:bold;font-size:7.5pt;">(Address of principal executive offices, including zip code)</font>
		</p>
		<p style="margin:9pt 1.6pt 0pt 0pt;text-indent:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">(650) 697-3939</font>
		</p>
		<p style="margin:0pt 1.6pt 0pt 0pt;text-indent:0pt;text-align:center;font-family:Times New Roman;font-size: 7pt">
			<font style="display: inline;font-weight:bold;font-size:7.5pt;">(Registrant&#x2019;s telephone number, including area code)</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">(see General Instruction A.2. below)</font><font style="display: inline;">:</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 1.6pt 0pt 0pt;text-indent:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:12pt 1.45pt 0pt 22.5pt;text-indent: -22.5pt;font-family:Times New Roman;font-size: 14pt">
						<font style="display: inline;font-size:14pt;">&#x2610;</font><font style="display: inline;font-size:14pt;font-family:Wingdings;;font-size: 14pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 22pt 0pt 0pt;"></font><font style="display: inline;font-weight:bold;font-size:11pt;"></font><font style="display: inline;font-size:11pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:12pt 1.45pt 0pt 22.5pt;text-indent: -22.5pt;font-family:Times New Roman;font-size: 14pt">
						<font style="display: inline;font-size:14pt;">&#x2610;</font><font style="display: inline;font-size:14pt;font-family:Wingdings;;font-size: 14pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 22pt 0pt 0pt;"></font><font style="display: inline;font-weight:bold;font-size:11pt;"></font><font style="display: inline;font-size:11pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:12pt 1.45pt 0pt 22.5pt;text-indent: -22.5pt;font-family:Times New Roman;font-size: 14pt">
						<font style="display: inline;font-size:14pt;">&#x2610;</font><font style="display: inline;font-size:14pt;font-family:Wingdings;;font-size: 14pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 22pt 0pt 0pt;"></font><font style="display: inline;font-weight:bold;font-size:11pt;"></font><font style="display: inline;font-size:11pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:12pt 1.45pt 0pt 22.5pt;text-indent: -22.5pt;font-family:Times New Roman;font-size: 14pt">
						<font style="display: inline;font-size:14pt;">&#x2610;</font><font style="display: inline;font-size:14pt;font-family:Wingdings;;font-size: 14pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 22pt 0pt 0pt;"></font><font style="display: inline;font-size:11pt;"></font><font style="display: inline;font-size:11pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:3pt 1.45pt 0pt 0pt;text-indent:0pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-size:11pt;">&#xFEFF;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:3pt 1.45pt 0pt 0pt;text-indent:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
			&nbsp;
		</p></div><div style="margin-left:72pt;margin-right:54pt;">
		<p style="margin:0pt;font-weight:bold;text-indent:0pt;font-family:Times New Roman;font-size: 11pt">

		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;font-weight:bold;text-indent:0pt;font-family:Times New Roman;;font-size: 11pt"><font style="display: inline;">Item 1.01</font><font style="display: inline;">.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;"> Entry into a Material </font><font style="display: inline;">Definitive Agreement.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">On </font><font style="display: inline;">February </font><font style="display: inline;">7</font><font style="display: inline;">, 2017, </font><font style="display: inline;">Pulse Biosciences</font><font style="display: inline;">, Inc. (the &#x201C;Company&#x201D;) entered into a securities purchase agreement (the &#x201C;Purchase Agreement&#x201D;) with </font><font style="display: inline;">Robert W. Duggan</font><font style="display: inline;"> and Maky </font><font style="display: inline;">Zanganeh</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">(the &#x201C;Investor</font><font style="display: inline;">s</font><font style="display: inline;">&#x201D;), pursuant to which the Company, in a private placement, agreed to issue and sell to the Investor</font><font style="display: inline;">s</font><font style="display: inline;"> an aggregate of </font><font style="display: inline;">819,673</font><font style="display: inline;"> shares of the Company&#x2019;</font><font style="display: inline;">s common stock, par value $0.0</font><font style="display: inline;">01 per share (the &#x201C;Common Stock&#x201D;), at a price per share of </font><font style="display: inline;">$</font><font style="display: inline;">6.10</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">(the &#x201C;</font><font style="display: inline;">Shares&#x201D;), for gross proceeds </font><font style="display: inline;">of approximately $</font><font style="display: inline;">5</font><font style="display: inline;"> million</font><font style="display: inline;"> (the &#x201C;Private Placement&#x201D;). The Company intends to use the net proceeds from the Private Placement&nbsp;for working capital or o</font><font style="display: inline;">ther general corporate purposes</font><font style="display: inline;">.&nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">In connection with the Private Placement, the Company has granted certain registration rights to the Investors, pursuant to which, among other things, the Company will prepare and file with the</font><font style="display: inline;"> Securities and Exchange Commission (the &#x201C;SEC&#x201D;) a registration statement</font><font style="display: inline;"> to register for resale the Shares on or prior to July 31, 2017</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">The foregoing description of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Purchase Agree</font><font style="display: inline;">ment, which is filed as Exhibit</font><font style="display: inline;"> 10.1 to this Current Report on Form 8-K and incorporated herein by reference.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">The representations, warranties and covenants contained in the Purchase Agreement were made solely for the benefit of the parties to the Purchase Agreement and may be subject to limitations agreed upon by the contracting parties. Accordingly, the Purchase Agreement is incorporated herein by reference only to provide investors with information regarding the terms of the Purchase Agreement and not to provide investors with any other factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company&#x2019;s periodic reports and other filings with the </font><font style="display: inline;">S</font><font style="display: inline;">EC</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-weight:bold;text-indent:0pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">Item&nbsp;3.02</font><font style="display: inline;">.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Unregistered Sales of Equity Securities. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">Pursuant to the Private Placement described in Item&nbsp;1.01 of this Current Report on Form 8-K, which description is incorporated by reference into this Item&nbsp;3.02 in its entirety, on </font><font style="display: inline;">February </font><font style="display: inline;">7</font><font style="display: inline;">, 2017, the Company sold the Shares to &#x201C;accredited investor</font><font style="display: inline;">s</font><font style="display: inline;">,&#x201D; as that term is defined in the Securities Act of 1933, as amended (the &#x201C;Securities Act&#x201D;), in reliance on the exemption from registration afforded by Section&nbsp;4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act and corresponding provisions of state securities or &#x201C;blue sky&#x201D; laws. </font><font style="display: inline;">T</font><font style="display: inline;">he Investor</font><font style="display: inline;">s</font><font style="display: inline;"> represented that </font><font style="display: inline;">they were</font><font style="display: inline;"> acquiring the Shares for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. Accordingly, the Shares have not been registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of Common Stock or other securities of the Company. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-weight:bold;text-indent:0pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">Item 5.02.&nbsp;&nbsp;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">E</font><font style="display: inline;">ffective as of </font><font style="display: inline;">February </font><font style="display: inline;">9</font><font style="display: inline;">, 2017</font><font style="display: inline;">, the </font><font style="display: inline;">Board of Directors </font><font style="display: inline;">of </font><font style="display: inline;">the Company </font><font style="display: inline;">(the &#x201C;Board&#x201D;) appointed Maky Zanganeh as a director, to serve until the Company&#x2019;s 2017 annual meeting of stockholders. There are no related person transactions within the meaning of Item 404(a) of Regulation S-K promulgated by the </font><font style="display: inline;">SEC</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">between Ms. Zanganeh and the Company required to be disclosed herein.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;font-weight:bold;text-indent:0pt;font-family:Times New Roman;font-size: 11pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-indent:0pt;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:12pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;font-weight:bold;text-indent:0pt;font-family:Times New Roman;;font-size: 11pt"><font style="display: inline;">Item 5.03.&nbsp;&nbsp;Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:18pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-weight:bold;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">(a)</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-weight:bold;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:normal;">On and effective</font><font style="display: inline;font-weight:normal;"> as of</font><font style="display: inline;font-weight:normal;">&nbsp;</font><font style="display: inline;font-weight:normal;">February </font><font style="display: inline;font-weight:normal;">9</font><font style="display: inline;font-weight:normal;">, 2017</font><font style="display: inline;font-weight:normal;">, the Board approved </font><font style="display: inline;font-weight:normal;">the amendment and restatement of</font><font style="display: inline;font-weight:normal;"> the Company&#x2019;s Bylaws (the &#x201C;Bylaws&#x201D;), to</font><font style="display: inline;font-weight:normal;">, among other things, change the provisions regarding the number of members of the Board </font><font style="display: inline;font-weight:normal;">(the &#x201C;</font><font style="display: inline;font-weight:normal;">Amended and Restated </font><font style="display: inline;font-weight:normal;">Bylaw&#x201D;). The Bylaw Amendment provides that the </font><font style="display: inline;font-weight:normal;">B</font><font style="display: inline;font-weight:normal;">oard shall consist of </font><font style="display: inline;font-weight:normal;">two</font><font style="display: inline;font-weight:normal;"> or more members, </font><font style="display: inline;font-weight:normal;">and that the number of directors </font><font style="display: inline;font-weight:normal;">shall be determined from time to time solely by resolution of the </font><font style="display: inline;font-weight:normal;">B</font><font style="display: inline;font-weight:normal;">oard</font><font style="display: inline;font-weight:normal;"> &nbsp;u</font><font style="display: inline;font-weight:normal;">nless the certificate of incorporation fi</font><font style="display: inline;font-weight:normal;">xes the number of directors</font><font style="display: inline;font-weight:normal;">.</font><font style="display: inline;font-weight:normal;">&nbsp;</font><font style="display: inline;font-weight:normal;">The foregoing summary is qualified in its entirety by reference to the </font><font style="display: inline;font-weight:normal;">Amended and Restated </font><font style="display: inline;font-weight:normal;">Bylaws, which is filed as Exhibit 3.1 to this Current Report </font><font style="display: inline;font-weight:normal;">on Form 8-K </font><font style="display: inline;font-weight:normal;">and incorporated by reference herein. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-indent:0pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">Item 8.01.&nbsp; </font><font style="display: inline;">Other Events</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">T</font><font style="display: inline;">he Company issued a press release announcing the Private Placement </font><font style="display: inline;">on February </font><font style="display: inline;">10</font><font style="display: inline;">, 2017</font><font style="display: inline;">. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-weight:bold;text-indent:0pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">Item&nbsp;9.01</font><font style="display: inline;">.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;"> Financial Statements and Exhibits. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:18pt;font-family:Times New Roman;font-size: 11pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:6pt;"><font style="display: inline;font-weight:bold;">(d)</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-weight:bold;"></font><font style="display: inline;font-weight:bold;">Exhibits.</font><font style="display: inline;">&nbsp;</font></font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:144.00pt;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:341.50pt;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:144.00pt;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-indent:0pt;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-size:9pt;">Exhibit No</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:341.50pt;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-indent:0pt;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-size:9pt;">Description</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:144.00pt;border-top:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-indent:0pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;">3.1</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:341.50pt;border-top:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-indent:0pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;">Amended and Restated Bylaws of Pulse Biosciences, Inc.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:144.00pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-indent:0pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;">10.1</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:341.50pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-indent:0pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;">Securities Purchase Agreement, dated </font><font style="display: inline;">February</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">7</font><font style="display: inline;">, 2017, by and between </font><font style="display: inline;">Pulse Biosciences</font><font style="display: inline;">, Inc. and </font><font style="display: inline;">certain purchasers</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:144.00pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-indent:0pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;">99.1</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:341.50pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-indent:0pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;">Press Release issued by Pulse Biosciences, Inc. dated February 10, 2017</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-indent:0pt;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;">-</font><font style="font-family:Times New Roman;font-size:11pt;display: inline;"></font><font style="font-family:Times New Roman;font-size:11pt;display: inline;">2</font><font style="font-family:Times New Roman;font-size:11pt;display: inline;"></font><font style="font-family:Times New Roman;font-size:11pt;display: inline;">-</font>

		</p>

		<p style="margin:0pt;text-indent:0pt;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;;font-size: 11pt"><font style="display: inline;"></font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:0pt;text-align:center;font-weight:bold;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">SIGNATURES</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:12pt 0pt 0pt 252pt;line-height:97.08%;text-indent: -252pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 11pt">
			<a name="TBLSigSig"></a><font style="text-indent:0pt;margin-left:-252pt; padding-right:250.6pt;"><font style="display: inline;">Date: </font><font style="display: inline;">February </font><font style="display: inline;">10</font><font style="display: inline;">, 2017</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;text-transform:uppercase;"></font><font style="display: inline;font-weight:bold;text-transform:uppercase;">Pulse Biosciences, Inc.</font></font>
		</p>
		<p style="margin:12pt 0pt 0pt 252pt;line-height:97.08%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:0pt;font-family:Times New Roman;font-size: 11pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:7.60000000000002pt;"><font style="display: inline;">By:</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:206.8pt;text-align:left"><font style="display: inline;"></font><font style="display: inline;text-decoration:underline;">&nbsp;</font><font style="display: inline;font-style:italic;text-decoration:underline;">/s/ Brian B. Dow</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;text-decoration:underline;"></font></font>
		</p>
		<p style="margin:0pt 0pt 0pt 252pt;line-height:97.08%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:0pt;font-family:Times New Roman;font-size: 11pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:19.6pt;"></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;"></font><font style="display: inline;">Brian B. Dow</font></font>
		</p>
		<p style="margin:0pt 0pt 0pt 252pt;line-height:97.08%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:0pt;font-family:Times New Roman;font-size: 11pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:19.6pt;"></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;"></font><font style="display: inline;font-style:italic;">Senior Vice President and </font></font>
		</p>
		<p style="margin:0pt 0pt 0pt 252pt;line-height:97.08%;border-top:1pt none #D9D9D9 ;text-indent:0pt;font-family:Times New Roman;font-size: 11pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:19.6pt;"></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-style:italic;"></font><font style="display: inline;font-style:italic;">Chief Financial Officer</font></font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-indent:0pt;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;">-</font><font style="font-family:Times New Roman;font-size:11pt;display: inline;"></font><font style="font-family:Times New Roman;font-size:11pt;display: inline;">3</font><font style="font-family:Times New Roman;font-size:11pt;display: inline;"></font><font style="font-family:Times New Roman;font-size:11pt;display: inline;">-</font>

		</p>

		<p style="margin:0pt;text-indent:0pt;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-size:10pt;"></font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:center;font-weight:bold;font-family:Times New Roman;font-size: 11pt">
			<a name="TBLExhibitIndex"></a><font style="display: inline;">INDEX TO EXHIBITS</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:77.40pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt;">
					<p style="margin:12pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:400.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt;">
					<p style="margin:12pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.40pt;padding:0pt 6.5pt;">
					<p style="margin:0pt 0pt 3pt;border-bottom:1pt solid #000000 ;text-align:center;text-indent:0pt;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-size:9pt;">Exhibit</font><br /><font style="display: inline;font-weight:bold;font-size:9pt;">Number</font></p>
				</td>
				<td valign="bottom" style="width:400.50pt;padding:0pt 6.5pt;">
					<p style="margin:0pt 0pt 3pt;border-bottom:1pt solid #000000 ;text-align:center;text-indent:0pt;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;font-size:9pt;">Description</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:77.40pt;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3.1&nbsp;
				</td>
				<td valign="top" style="width:400.50pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;text-indent:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Amended and Restated Bylaws of Pulse Biosciences, Inc.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:77.40pt;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.1&nbsp;
				</td>
				<td valign="top" style="width:400.50pt;padding:0pt 6.5pt;">
					<p style="margin:6pt 0pt 0pt;text-indent:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Securities Purchase Agreement, dated </font><font style="display: inline;">February</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">7</font><font style="display: inline;">, 2017, by and between </font><font style="display: inline;">Pulse Biosciences</font><font style="display: inline;">, Inc. and </font><font style="display: inline;">certain purchasers </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:77.40pt;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">99.1&nbsp;
				</td>
				<td valign="top" style="width:400.50pt;padding:0pt 6.5pt;">
					<p style="margin:6pt 0pt 0pt;text-indent:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Press Release issued by Pulse Biosciences, Inc. dated February 10, 2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:77.40pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;text-indent:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:400.50pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;text-indent:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-indent:0pt;font-family:Times New Roman;font-size: 11pt">

			<font style="display: inline;">-</font><font style="font-family:Times New Roman;font-size:11pt;display: inline;"></font><font style="font-family:Times New Roman;font-size:11pt;display: inline;">4</font><font style="font-family:Times New Roman;font-size:11pt;display: inline;"></font><font style="font-family:Times New Roman;font-size:11pt;display: inline;">-</font>

		</p>

		<p style="margin:0pt;text-indent:0pt;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "plse-20170210x8k.htm", "description": "8-K", "secsgml_size_bytes": 47384}]
{"company-data": {"conformed-name": "Pulse Biosciences, Inc.", "cik": "0001625101", "assigned-sic": "3841", "irs-number": "000000000", "state-of-incorporation": "NV", "fiscal-year-end": "1217"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-37744", "film-number": "17589917"}, "business-address": {"street1": "849 MITTEN ROAD", "street2": "SUITE 104", "city": "BURLINGAME", "state": "CA", "zip": "90401", "phone": "650-697-3939"}, "mail-address": {"street1": "849 MITTEN ROAD", "street2": "SUITE 104", "city": "BURLINGAME", "state": "CA", "zip": "90401"}, "former-company": {"former-conformed-name": "Electroblate, Inc.", "date-changed": "20141113"}}
8K 2017-02-10
﻿
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________
FORM 8-K
_______________________
CURRENT REPORT
Pursuant to S
ection 13 or 15(d)
of the
Securities Exchange A
ct of 1934
_______________________
Date of Report (date of earliest event reported):
February 7
, 2017
_______________________
Pulse Biosciences, Inc.
(Exact name of registrant as specified in its charter)
_______________________
﻿
﻿
Nevada
001-37744
46-5696597
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
﻿
849 Mitten Road
Burlingame, California 94010
(Address of principal executive offices, including zip code)
(650) 697-3939
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below)
:
﻿
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
﻿
﻿
﻿
Item 1.01
.
Entry into a Material
Definitive Agreement.
On
February
7
, 2017,
Pulse Biosciences
, Inc. (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with
Robert W. Duggan
and Maky
Zanganeh
(the "Investor
s
"), pursuant to which the Company, in a private placement, agreed to issue and sell to the Investor
s
an aggregate of
819,673
shares of the Company'
s common stock, par value $0.0
01 per share (the "Common Stock"), at a price per share of
$
6.10
(the "
Shares"), for gross proceeds
of approximately $
5
million
(the "Private Placement"). The Company intends to use the net proceeds from the Private Placement for working capital or o
ther general corporate purposes
.
In connection with the Private Placement, the Company has granted certain registration rights to the Investors, pursuant to which, among other things, the Company will prepare and file with the
Securities and Exchange Commission (the "SEC") a registration statement
to register for resale the Shares on or prior to July 31, 2017
.
The foregoing description of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Purchase Agree
ment, which is filed as Exhibit
10.1 to this Current Report on Form 8-K and incorporated herein by reference.
The representations, warranties and covenants contained in the Purchase Agreement were made solely for the benefit of the parties to the Purchase Agreement and may be subject to limitations agreed upon by the contracting parties. Accordingly, the Purchase Agreement is incorporated herein by reference only to provide investors with information regarding the terms of the Purchase Agreement and not to provide investors with any other factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company's periodic reports and other filings with the
S
EC
.
Item 3.02
.
Unregistered Sales of Equity Securities.
Pursuant to the Private Placement described in Item 1.01 of this Current Report on Form 8-K, which description is incorporated by reference into this Item 3.02 in its entirety, on
February
7
, 2017, the Company sold the Shares to "accredited investor
s
," as that term is defined in the Securities Act of 1933, as amended (the "Securities Act"), in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act and corresponding provisions of state securities or "blue sky" laws.
T
he Investor
s
represented that
they were
acquiring the Shares for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. Accordingly, the Shares have not been registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws.
Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of Common Stock or other securities of the Company.
Item 5.02.  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.
E
ffective as of
February
9
, 2017
, the
Board of Directors
of
the Company
(the "Board") appointed Maky Zanganeh as a director, to serve until the Company's 2017 annual meeting of stockholders. There are no related person transactions within the meaning of Item 404(a) of Regulation S-K promulgated by the
SEC
between Ms. Zanganeh and the Company required to be disclosed herein.
Item 5.03.  Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
(a)
On and effective
as of
February
9
, 2017
, the Board approved
the amendment and restatement of
the Company's Bylaws (the "Bylaws"), to
, among other things, change the provisions regarding the number of members of the Board
(the "
Amended and Restated
Bylaw"). The Bylaw Amendment provides that the
B
oard shall consist of
two
or more members,
and that the number of directors
shall be determined from time to time solely by resolution of the
B
oard
u
nless the certificate of incorporation fi
xes the number of directors
.
The foregoing summary is qualified in its entirety by reference to the
Amended and Restated
Bylaws, which is filed as Exhibit 3.1 to this Current Report
on Form 8-K
and incorporated by reference herein.
﻿
Item 8.01.
Other Events
.
T
he Company issued a press release announcing the Private Placement
on February
10
, 2017
. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.
﻿
Item 9.01
.
Financial Statements and Exhibits.
(d)
Exhibits.
﻿
﻿
Exhibit No
Description
3.1
Amended and Restated Bylaws of Pulse Biosciences, Inc.
10.1
Securities Purchase Agreement, dated
February
7
, 2017, by and between
Pulse Biosciences
, Inc. and
certain purchasers
99.1
Press Release issued by Pulse Biosciences, Inc. dated February 10, 2017
﻿
-
2
-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
﻿
Date:
February
10
, 2017
Pulse Biosciences, Inc.
By:
/s/ Brian B. Dow
Brian B. Dow
Senior Vice President and
Chief Financial Officer
-
3
-
﻿
INDEX TO EXHIBITS
﻿
﻿
Exhibit
Number
Description
3.1
Amended and Restated Bylaws of Pulse Biosciences, Inc.
10.1
Securities Purchase Agreement, dated
February
7
, 2017, by and between
Pulse Biosciences
, Inc. and
certain purchasers
99.1
Press Release issued by Pulse Biosciences, Inc. dated February 10, 2017
﻿
﻿
-
4
-